Clinical Research Directory
Browse clinical research sites, groups, and studies.
Treating Schizophrenia by Correcting Abnormal Brain Development
Sponsor: Beth Israel Deaconess Medical Center
Summary
The purpose of this study is to determine whether treatment with tiagabine (Gabitril) during the early course of schizophrenia can fundamentally correct the brain deficits associated with the disease. This study is funded by the National Institutes of Health.
Official title: Addition of Tiagabine to Second-Generation Antipsychotics in the Treatment of Recent-Onset Schizophrenia by Modification of Developmental Reorganization of the Prefrontal Cortex
Key Details
Gender
All
Age Range
18 Years - 25 Years
Study Type
INTERVENTIONAL
Enrollment
36
Start Date
2003-11
Completion Date
2026-09
Last Updated
2025-01-27
Healthy Volunteers
No
Conditions
Interventions
Tiagabine
Up to 36 mg daily
Placebo
Placebo
Locations (1)
Beth Israel Deaconess Medical Center
Boston, Massachusetts, United States